Lrrk2 localization in the primate basal ganglia and thalamus: A light and electron microscopic analysis in monkeys

Experimental Neurology

Volumn 224, Issue 2, 2010, Pages 438-447

  Lee, H ^a   Melrose, H L ^c   Yue, M ^c   Pare, Jean Francois ^a   Farrer, M J ^c   Smith, Y ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Caudate nucleus; Centromedian nucleus; Dopamine; Globus pallidus; Parkinson's disease; Putamen; Striatum; Substantia nigra; Subthalamic nucleus

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PARVALBUMIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CELLULAR DISTRIBUTION; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITE; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; GABAERGIC SYSTEM; GENE MUTATION; GLOBUS PALLIDUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MEYNERT BASAL NUCLEUS; MONKEY; NERVE ENDING; NERVE PROJECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; THALAMUS; VENTRAL TEGMENTUM;

ANIMALS; BASAL GANGLIA; CAUDATE NUCLEUS; MACACA MULATTA; PROTEIN-SERINE-THREONINE KINASES; PUTAMEN; THALAMUS;

EID: 77954659530     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.05.004     Document Type: Article

References (58)

1. Anand V.S., Braithwaite S.P. LRRK2 in Parkinson's disease: biochemical functions. FEBS J. 2009, 276:6428-6435.
2. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L., Emson P.C., Torp R., Ottersen O.P., Dawson T.M., Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60:557-569.
3. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007, 30:211-219.
4. Celio M.R., Baier W., Scharer L., de Viragh P.A., Gerday C. Monoclonal antibodies directed against the calcium binding protein parvalbumin. Cell Calcium 1988, 9:81-86.
5. Covy J.P., Yuan W., Waxman E.A., Hurtig H.I., Van Deerlin V.M., Giasson B.I. Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. Mov. Disord. 2009, 24:32-39.
6. Fortin M., Asselin M.C., Parent A. Calretinin immunoreactivity in the thalamus of the squirrel monkey. J. Chem. Neuroanat. 1996, 10:101-117.
7. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 2002, 51:296-301.
8. Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O., Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 2006, 59:714-719.
9. Gandhi P.N., Wang X., Zhu X., Chen S.G., Wilson-Delfosse A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 2008, 86:1711-1720.
10. Gandhi P.N., Chen S.G., Wilson-Delfosse A.L. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J. Neurosci. Res. 2009, 87:1283-1295.
11. Gasser T. Molecular pathogenesis of Parkinson's disease: insights from genetic studies. Expert Rev. Mol. Med. 2009, 11:e22.
12. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 2006, 59:315-322.
13. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration?. J. Neurochem. 2009, 110:1514-1522.
14. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 2006, 15:223-232.
15. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
16. Halliday G.M., Macdonald V., Henderson J.M. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 2005, 128:2272-2280.
17. Hatano T., Kubo S., Imai S., Maeda M., Ishikawa K., Mizuno Y., Hattori N. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 2007, 16:678-690.
18. Henderson J.M., Carpenter K., Cartwright H., Halliday G.M. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 2000, 123(Pt 7):1410-1421.
19. Henderson J.M., Carpenter K., Cartwright H., Halliday G.M. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann. Neurol. 2000, 47:345-352.
20. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., Waldvogel H.J., Arai H., Dawson T.M., Moore D.J., Emson P.C. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007, 1155:208-219.
21. Higashi S., Moore D.J., Colebrooke R.E., Biskup S., Dawson V.L., Arai H., Dawson T.M., Emson P.C. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 2007, 100:368-381.
22. Higashi S., Moore D.J., Yamamoto R., Minegishi M., Sato K., Togo T., Katsuse O., Uchikado H., Furukawa Y., Hino H., Kosaka K., Emson P.C., Wada K., Dawson V.L., Dawson T.M., Arai H., Iseki E. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in Lewy body disease. J. Neuropathol. Exp. Neurol. 2009, 68:994-1005.
23. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
24. Jones E.G., Hendry S.H. Differential calcium binding protein immunoreactivity distinguishes classes of relay neurons in monkey thalamic nuclei. Eur. J. Neurosci. 1989, 1:222-246.
25. Lesage S., Leutenegger A.L., Brice A. LRRK2: a gene belonging to the ROCO family is implicated in the Parkinson's disease. Med. Sci. (Paris) 2005, 21:1015-1017.
26. Lesage S., Durr A., Brice A. LRRK2: a link between familial and sporadic Parkinson's disease?. Pathol. Biol. (Paris) 2007, 55:107-110.
27. Liou G.Y., Gallo K.A. New biochemical approaches towards understanding the Parkinson's disease-associated kinase, LRRK2. Biochem. J. 2009, 424:e1-e3.
28. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
29. Mallet N., Le Moine C., Charpier S., Gonon F. Feedforward inhibition of projection neurons by fast-spiking GABA interneurons in the rat striatum in vivo. J. Neurosci. 2005, 25:3857-3869.
30. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29:286-293.
31. Melrose H. Update on the functional biology of Lrrk2. Future Neurol. 2008, 3:669-681.
32. Melrose H., Lincoln S., Tyndall G., Dickson D., Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006, 139:791-794.
33. Melrose H.L., Kent C.B., Taylor J.P., Dachsel J.C., Hinkle K.M., Lincoln S.J., Mok S.S., Culvenor J.G., Masters C.L., Tyndall G.M., Bass D.I., Ahmed Z., Andorfer C.A., Ross O.A., Wszolek Z.K., Delldonne A., Dickson D.W., Farrer M.J. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007, 147:1047-1058.
34. Miklossy J., Arai T., Guo J.P., Klegeris A., Yu S., McGeer E.G., McGeer P.L. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 2006, 65:953-963.
35. Paquet M., Smith Y. Differential localization of AMPA glutamate receptor subunits in the two segments of the globus pallidus and the substantia nigra pars reticulata in the squirrel monkey. Eur. J. Neurosci. 1996, 8:229-233.
36. Parisiadou L., Xie C., Cho H.J., Lin X., Gu X.L., Long C.X., Lobbestael E., Baekelandt V., Taymans J.M., Sun L., Cai H. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 2009, 29:13971-13980.
37. Percheron G., Francois C., Talbi B., Yelnik J., Fenelon G. The primate motor thalamus. Brain Res. Brain Res. Rev. 1996, 22:93-181.
38. Qing H., Zhang Y., Deng Y., McGeer E.G., McGeer P.L. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 2009, 390:1229-1234.
39. Raju D.V., Shah D.J., Wright T.M., Hall R.A., Smith Y. Differential synaptology of vGluT2-containing thalamostriatal afferents between the patch and matrix compartments in rats. J. Comp. Neurol. 2006, 499:231-243.
40. Shin N., Jeong H., Kwon J., Heo H.Y., Kwon J.J., Yun H.J., Kim C.H., Han B.S., Tong Y., Shen J., Hatano T., Hattori N., Kim K.S., Chang S., Seol W. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 2008, 314:2055-2065.
41. Simon-Sanchez J., Herranz-Perez V., Olucha-Bordonau F., Perez-Tur J. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 2006, 23:659-666.
42. Smith Y., Bolam J.P. Combined approaches to experimental neuroanatomy: combined tracing and imunocytochemical techniques for the study of neuronal microcircuits. Practical Approach Series; "Experimental Neuroanatomy: a Practical Approach" 1992, 239-266. Oxford University Press, Oxford, UK. J.P. Bolam (Ed.).
43. Smith Y., Villalba R. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov. Disord. 2008, 23(Suppl 3):S534-S547.
44. Smith Y., Raju D.V., Pare J.F., Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 2004, 27:520-527.
45. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
46. Smith Y., Raju D., Nanda B., Pare J.F., Galvan A., Wichmann T. The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states. Brain Res. Bull. 2009, 78:60-68.
47. Taylor J.P., Mata I.F., Farrer M.J. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. Trends Mol. Med. 2006, 12:76-82.
48. Taymans J.M., Van den Haute C., Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 2006, 98:951-961.
49. Tepper J.M., Bolam J.P. Functional diversity and specificity of neostriatal interneurons. Curr. Opin. Neurobiol. 2004, 14:685-692.
50. Villalba R.M., Lee H., Smith Y. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp. Neurol. 2009, 215:220-227.
51. Waxman E.A., Covy J.P., Bukh I., Li X., Dawson T.M., Giasson B.I. Leucone-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J. Neuropathol. Exp. Neurol. 2009, 68:785-796.
52. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. PNAS USA 2005, 102:16842-16847.
53. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16:223-232.
54. Westerlund M., Belin A.C., Anvret A., Bickford P., Olson L., Galter D. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson's disease. Neuroscience 2008, 152:429-436.
55. Wu Y., Parent A. Striatal interneurons expressing calretinin, parvalbumin or NADPH-diaphorase: a comparative study in the rat, monkey and human. Brain Res. 2000, 863:182-191.
56. Zhu X., Babar A., Siedlak S.L., Yang Q., Ito G., Iwatsubo T., Smith M.A., Perry G., Chen S.G. LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener. 2006, 1:17.
57. Zhu X., Siedlak S.L., Smith M.A., Perry G., Chen S.G. LRRK2 protein is a component of Lewy bodies. Ann. Neurol. 2006, 60:617-618. author reply 618-619.
58. Zimmermann L., Schwaller B. Monoclonal antibodies recognizing epitopes of calretinin. Dependence of Ca2+-binding status and difference in antigen accessibility in colon cancer cells. Cell Calcium 2002, 31:13-25.